NASDAQ:TGTX TG Therapeutics (TGTX) Stock Price, News & Analysis $53.91 -0.38 (-0.70%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$53.60 -0.31 (-0.58%) As of 10/5/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TG Therapeutics Stock (NASDAQ:TGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TG Therapeutics alerts:Sign Up Key Stats Today's Range$53.32▼$54.7550-Day Range$46.17▼$58.1152-Week Range$26.76▼$59.30Volume1.55 million shsAverage Volume1.74 million shsMarket Capitalization$8.25 billionP/E Ratio19.68Dividend YieldN/APrice Target$63.00Consensus RatingHold Company Overview TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways. TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. BRIUMVI is administered by intravenous infusion and is intended to reduce disease activity and delay disability progression. The company commercializes BRIUMVI in the United States and continues to evaluate opportunities to expand its use in additional immune-mediated conditions. TG Therapeutics is led by Michael S. Weiss, who serves as chairman and chief executive officer. The company has historically focused its development efforts on therapies for B-cell malignancies and autoimmune diseases.AI Generated. May Contain Errors. Read More TG Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTGTX MarketRank™: TG Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 231st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingTG Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialTG Therapeutics has a consensus price target of $63.00, representing about 16.9% upside from its current price of $53.91.Amount of Analyst CoverageTG Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TG Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth188.04% Earnings GrowthEarnings for TG Therapeutics are expected to grow by 188.04% in the coming year, from $0.92 to $2.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TG Therapeutics is 19.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.Price to Earnings Ratio vs. SectorThe P/E ratio of TG Therapeutics is 19.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.Price to Earnings Growth RatioTG Therapeutics has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTG Therapeutics has a P/B Ratio of 13.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TG Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.62% of the float of TG Therapeutics has been sold short.Short Interest Ratio / Days to CoverTG Therapeutics has a short interest ratio ("days to cover") of 18.54, which indicates bearish sentiment.Change versus previous monthShort interest in TG Therapeutics has recently increased by 0.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTG Therapeutics does not currently pay a dividend.Dividend GrowthTG Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows8 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,800.00 in company stock.Percentage Held by Insiders8.87% of the stock of TG Therapeutics is held by insiders.Percentage Held by Institutions58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TG Therapeutics' insider trading history. Receive TGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TGTX Stock News HeadlinesKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmSeptember 28, 2026 | prnewswire.comTG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Average Target Price of $63.00September 27, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Head-To-Head Comparison: Puma Biotechnology (NASDAQ:PBYI) & TG Therapeutics (NASDAQ:TGTX)September 26, 2026 | americanbankingnews.comTG Therapeutics Inc (TGTX)September 24, 2026 | ru.investing.comDow Jones futures fall after Nasdaq hits new high; SanDisk, Micron trigger buy signalsSeptember 23, 2026 | msn.comDow Jones futures: Nasdaq hits new high; SanDisk, Micron trigger buy signalsSeptember 22, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 SharesSeptember 15, 2026 | insidertrades.comSee More Headlines TGTX Stock Analysis - Frequently Asked Questions How have TGTX shares performed this year? TG Therapeutics' stock was trading at $29.81 at the start of the year. Since then, TGTX shares have increased by 80.8% and is now trading at $53.91. How were TG Therapeutics' earnings last quarter? TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings results on Monday, August, 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.31 by $0.26. The business's quarterly revenue was up 70.2% on a year-over-year basis. Read the conference call transcript. How do I buy shares of TG Therapeutics? Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TG Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/03/2026Today10/05/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TGTX's financial health is in the Green zone, according to TradeSmith. TGTX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TGTX Previous SymbolOTCMKTS:TGTX CIK1001316 Webwww.tgtherapeutics.com Phone(212) 554-4484Fax212-554-4531Employees399Year Founded1993Price Target and Rating Average Price Target for TG Therapeutics$63.00 High Price Target$86.00 Low Price Target$20.00 Potential Upside/Downside+16.9%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.74 Trailing P/E Ratio19.68 Forward P/E Ratio58.60 P/E Growth2.33Net Income$447.18 million Net Margins55.22% Pretax Margin12.71% Return on Equity73.49% Return on Assets34.14% Debt Debt-to-Equity Ratio1.23 Current Ratio4.27 Quick Ratio3.72 Sales & Book Value Annual Sales$799.54 million Price / Sales10.32 Cash Flow$2.78 per share Price / Cash Flow19.38 Book Value$4.08 per share Price / Book13.21Miscellaneous Outstanding Shares153,069,000Free Float139,492,000Market Cap$8.25 billion OptionableOptionable Beta1.80 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TGTX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
